✦ LIBER ✦

Clinical Experience with CD3 X CD19 Bispecific Antibodies in Patients with B Cell Malignancies

✍ Scribed by DE GAST, GIJSBERT C.; VAN HOUTEN, ANJA A.; HAAGEN, INEZ-ANNE; KLEIN, SIGRID; DE WEGER, ROEL A.; VAN DIJK, ANET; PHILLIPS, JENNY; CLARK, MIKE; BAST, BERT J.E.G.

Book ID: 125543472
Publisher: Mary Ann Liebert
Year: 1995
Tongue: English
Weight: 676 KB
Volume: 4
Category: Article
ISSN: 1061-6128
DOI: 10.1089/scd.1.1995.4.433

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Locoregional treatment of low-grade B-ce

Locoregional treatment of low-grade B-cell lymphoma with CD3×CD19 bispecific antibodies and CD28 costimulation: I. Clinical phase I evaluation

✍ Oliver Manzke; Hans Tesch; Peter Borchmann; Jürgen Wolf; Klaus Lackner; Axel Gos 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 240 KB

We describe the first clinical application of T-cell-recruiting bispecific antibodies directly into the tumor without the need to preactivate the effector cells. In a Phase I clinical trial, 10 patients with low-grade B-cell lymphoma were treated by a single locoregional injection of CD3؋CD19 bispec

Costimulation with agonistic anti-CD28 a

Costimulation with agonistic anti-CD28 antibodies prevents T cell apoptosis and is required for efficient immunotherapy with CD3x19 bispecific antibodies in B cell lymphoma

✍ P.T. Daniel; A. Kroidl; A. Pezzutto; G. Moldenhauer; B. Dörken 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 137 KB

Immunotherapy of B-Cell Lymphoma with an

Immunotherapy of B-Cell Lymphoma with an Engineered Bispecific Antibody Targeting CD19 and CD5

✍ Lüttgau, Sandra; Deppe, Dorothée; Meyer, Saskia; Fertig, Regina; Panjideh, Hosse 📂 Article 📅 2013 🏛 MDPI AG 🌐 English ⚖ 588 KB

Antibody against CD20 in patients with B

Antibody against CD20 in patients with B cell malignancy

✍ Penelope J. Adamson; Heddy Zola; Ian C. Nicholson; Glenn Pilkington; Arthur Hohm 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 64 KB

CD8 T cell activation after intravenous

CD8 T cell activation after intravenous administration of CD3×CD19 bispecific antibody in patients with non-Hodgkin lymphoma

✍ Gijsbert C. de Gast; Inez-Anne Haagen; Anja A. van Houten; Sigrid C. Klein; Ashl 📂 Article 📅 1995 🏛 Springer-Verlag 🌐 English ⚖ 710 KB

Effect of tetravalent bispecific CD19×CD

Effect of tetravalent bispecific CD19×CD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells

✍ Uwe Reusch; Fabrice Le Gall; Manfred Hensel; Gerhard Moldenhauer; Anthony D. Ho; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 284 KB

## Abstract To develop an effective antitumor immunotherapy for B‐lineage non‐Hodgkin's lymphoma, we constructed a tetravalent tandem diabody (tanDb) specific for both human CD19 (B‐cell marker) and CD3 (T‐cell antigen). Here, we report the effective killing of malignant primary B cells from patien